493 related articles for article (PubMed ID: 20030477)
21. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Tan KH
Cochrane Database Syst Rev; 2006 Jul; (3):CD002009. PubMed ID: 16855982
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
Brigg Turner R; Elbarbry F; Biondo L
J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
[TBL] [Abstract][Full Text] [Related]
23. Aminoglycosides are useful for severe respiratory tract infections.
Craig WA; Andes D
Semin Respir Infect; 1997 Dec; 12(4):271-7. PubMed ID: 9436954
[TBL] [Abstract][Full Text] [Related]
24. [Tobramycin--clinical pharmacology and chemotherapy].
Periti P
J Chemother; 1996 Jan; 8 Suppl 1():3-30. PubMed ID: 8948764
[TBL] [Abstract][Full Text] [Related]
25. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
[TBL] [Abstract][Full Text] [Related]
26. Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections.
Paradisi F; Corti G
J Chemother; 1995 Aug; 7(4):338-43. PubMed ID: 8568544
[TBL] [Abstract][Full Text] [Related]
27. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
Madsen V; Lind A; Rasmussen M; Coulthard K
J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
[TBL] [Abstract][Full Text] [Related]
28. Once daily versus multiple daily dosing with intravenous aminoglycosides for cystic fibrosis.
Tan K; Bunn H
Cochrane Database Syst Rev; 2000; (4):CD002009. PubMed ID: 11034740
[TBL] [Abstract][Full Text] [Related]
29. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
30. Extended dosage intervals for aminoglycosides.
Rodman DP; Maxwell AJ; McKnight JT
Am J Hosp Pharm; 1994 Aug; 51(16):2016-21. PubMed ID: 7977422
[TBL] [Abstract][Full Text] [Related]
31. [Daily single-dose aminoglycoside administration. Therapeutic and economic benefits].
Knudsen LM; Frimodt-Møller N; Hansen MT; Hippe E
Ugeskr Laeger; 1993 May; 155(19):1436-41. PubMed ID: 8316969
[TBL] [Abstract][Full Text] [Related]
32. The place of tobramycin in lower respiratory tract infections (LRTI).
Gialdroni Grassi G
J Chemother; 1995 Aug; 7(4):344-54. PubMed ID: 8568545
[TBL] [Abstract][Full Text] [Related]
33. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
[TBL] [Abstract][Full Text] [Related]
34. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
Alghanem S; Paterson I; Touw DJ; Thomson AH
J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
[TBL] [Abstract][Full Text] [Related]
35. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.
Michalsen H; Bergan T
Scand J Infect Dis Suppl; 1981; 29():92-7. PubMed ID: 6947408
[TBL] [Abstract][Full Text] [Related]
36. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.
Prayle AP; Jain K; Touw DJ; Koch BC; Knox AJ; Watson A; Smyth AR
J Cyst Fibros; 2016 Jul; 15(4):510-7. PubMed ID: 26282839
[TBL] [Abstract][Full Text] [Related]
37. [Dosing aminoglycosides once a day].
Blaser J
Schweiz Med Wochenschr Suppl; 1996; 76():39S-48S. PubMed ID: 8677418
[TBL] [Abstract][Full Text] [Related]
38. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
Bates RD; Nahata MC; Jones JW; McCoy K; Young G; Cox S; Barson WJ
Chest; 1997 Nov; 112(5):1208-13. PubMed ID: 9367459
[TBL] [Abstract][Full Text] [Related]
40. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis.
Whitehead A; Conway SP; Etherington C; Caldwell NA; Setchfield N; Bogle S
Eur Respir J; 2002 Feb; 19(2):303-9. PubMed ID: 11866010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
